Yuichi Hikichi

TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens

Yuichi Hikichi, Kohei Honda, Kouki Hikami et al. · Molecular Cancer Therapeutics · 2011 · 77 citations · Full text

Tumor Biology, Orally Available, Mdr1 Expression +13

Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis

Hiroto Kita, Yuichi Hikichi, Kouki Hikami et al. · Journal of Gastroenterology · 2006 · 57 citations

Medicine, Microarray Data Analysis, Gastroenterology +11

Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors

Andre A. Kiryanov, Srinivasa Reddy Natala, Benjamin Jones et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 18 citations · Full text

Combinatorial Chemistry, Sar Development, Medicinal Chemistry +9

All-trans retinoic acid-induced ADAM28 degrades proteoglycans in human chondrocytes

Yuichi Hikichi, Koji Yoshimura, Masaharu Takigawa · Biochemical and Biophysical Research Communications · 2009 · 14 citations

Human Chondrocytes, Cartilage Degeneration, Matrix Biology +4